Adam Hosszu

Dr. Adam Hosszu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AHAdam Hosszu
Adam Hosszu
ATAkos R. Toth
Akos R. Toth
TLTamas Lakat
Tamas Lakat
GSGanna Stepanova
Ganna Stepanova
ZAZsuzsanna Antal
Zsuzsanna Antal
AFAndrea Fekete
Andrea Fekete
Kidney transplantation is the preferred treatment for patients with end-stage kidney disease. Maintaining organ viability between donation and transplantation, as well as minimizing ischemic injury, are critically important for long-term graft function and survival. Moreover, the increasing shortage of transplantable organs is a considerable problem; thus, optimizing the condition of grafts is a pivotal task. Here, rodent models of kidney transplantation and cold storage were used to demonstrate that supplementation of a preservation solution with Sigma-1 receptor (S1R) agonist fluvoxamine (FLU) reduces cold and warm ischemic injury. Post-transplant kidney function was improved, histological injury was mitigated, and mRNA expression of two tubular injury markers—kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin—was robustly reduced. In addition, renal inflammation was diminished, as shown by reduced leukocyte infiltration and pro-inflammatory cytokine expression. In the cold ischemia model, FLU ameliorated structural injury profoundly after 2 h as well as 24 h. The reduced number of TUNEL-positive and Caspase 3-positive cells suggests the anti-apoptotic effect of FLU. None of these beneficial effects of FLU were observed in S1R−/− mice. Of note, organ damage in FLU-treated kidneys after 24 h of cold storage was similar to just 2 h without FLU. These results indicate that S1R agonists can prolong storage time and have great potential in improving organ preservation and in alleviating the problem of organ shortages.

1 August 2024 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
TLTamas Lakat
Tamas Lakat
AFAndrea Fekete
Andrea Fekete
KDKornél Demeter
Kornél Demeter
ATAkos R. Toth
Akos R. Toth
ZVZoltan K. Varga
Zoltan K. Varga
AHAdam Hosszu
Adam Hosszu
Perinatal asphyxia (PA) poses a significant threat to multiple organs, particularly the kidneys. Diagnosing PA-associated kidney injury remains challenging and treatment options are inadequate. Furthermore, there is a lack of long-term follow-up data regarding the renal implications of PA. In this study, 7-day-old male Wistar rats were exposed to PA using a gas mixture (4% O2; 20% CO2 in N2 for 15 minutes) to investigate molecular pathways linked to renal tubular damage, hypoxia, angiogenesis, heat-shock response, inflammation, and fibrosis in the kidney. In a second experiment, adult rats with a history of PA were subjected to moderate renal ischemia-reperfusion (IR) injury to test the hypothesis that PA exacerbates renal susceptibility. Our results revealed an increased gene expression of renal injury markers (KIM-1, NGAL), hypoxic- and heat shock factors (HIF-1α, HSF-1, HSP-27), pro-inflammatory cytokines (IL-1ß, IL-6, TNF-α, MCP-1), and fibrotic markers (TGF-ß, CTGF, Fibronectin) promptly after PA. Moreover, a machine learning model was identified through Random Forest analysis, demonstrating an impressive classification accuracy (95.5%) for PA. Post-PA rats showed exacerbated functional decline and tubular injury and more intense hypoxic-, heat-shock-, pro-inflammatory-, and pro-fibrotic response after renal IRI compared to controls. In conclusion, PA leads to subclinical kidney injury, which may increase the susceptibility to subsequent renal damage later in life. Additionally, the parameters identified through Random Forest analysis provide a robust foundation for future biomarker research in the context of PA.

Verified
Journal Article
Open access
PDF file
RTRóbert Tarszabó
Róbert Tarszabó
BBBálint Bányai
Bálint Bányai
EREva Ruisanchez
Eva Ruisanchez
BPBorbála Péterffy
Borbála Péterffy
ÁKÁgnes Korsós-Novák
Ágnes Korsós-Novák
SVSzabolcs Várbíró
Szabolcs Várbíró
We examined the vasoactive effect of estradiol in a rat model of early PCOS and the influence of vitamin D deficiency (VDD). We created a model of chronic hyperandrogenism and VDD in adolescent female Wistar rats (N = 46) with four experimental groups: vitamin D supplemented (T-D+), VDD (T-D-), hyperandrogenic and vitamin D supplemented (T+D+), and hyperandrogenic and VDD (T+D-). T+ groups received an 8-week-long transdermal Androgel treatment, D-animals were on vitamin D-reduced diet and D+ rats were supplemented orally with vitamin D3. Estrogen-induced vasorelaxation of thoracic aorta segments were measured with a wire myograph system with or without the inhibition of endothelial nitric oxide synthase (eNOS) or cyclooxygenase-2 (COX-2). The distribution of estrogen receptor (ER), eNOS and COX-2 in the aortic wall was assessed by immunohistochemistry. VDD aortas showed significantly lower estradiol-induced relaxation independently of androgenic status that was further decreased by COX-2 inhibition. COX-2 inhibition failed to alter vessel function in D+ rats. Inhibition of eNOS abolished the estradiol-induced relaxation in all groups. Changes in vascular function in VDD were accompanied by significantly decreased ER and eNOS staining. Short-term chronic hyperandrogenism failed to, but VDD induced vascular dysfunction, compromised estrogen-dependent vasodilatation and changes in ER and eNOS immunostaining.

30 July 2021 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
OHOrsolya Horváth
Orsolya Horváth
KKKata Kelen
Kata Kelen
ZPZoltán Prohászka
Zoltán Prohászka
AHAdam Hosszu
Adam Hosszu
Attila SzaboAttila Szabo
Attila Szabo
GRGyörgy S. Reusz
György S. Reusz
Background: In atypical hemolytic-uremic syndrome (aHUS), various defects of the complement system have been reported to explain pathophysiology. Therapeutic options for complement inhibition are well-recognized; however, the links between various immune-derived diseases and aHUS are unclear, and their interference with treatment efficacy during long-term complement-blocking therapy is scarcely known. Case-diagnosis/treatment: We present a pediatric patient who developed aHUS with acute kidney injury in parallel with the onset of Crohn’s disease (CD), and who required long-term complement-blocking therapy with eculizumab (ECU). Unexpectedly, during the 6-year ECU treatment, an important intra-patient variation of the degree of complement inhibition was observed. In spite of continuous and stable doses of complement-blocking therapy, periods of incomplete blockade were observed in strong association with relapses of CD. When conventional and later biological therapy with adalimumab was introduced, with CD going into remission, complement blockade became complete again. Despite periodically low ECU levels and insufficient complement inhibition, no clinical or hematological signs of aHUS recurrence were detected during CD relapses. Conclusion: In aHUS cases secondary to CD, close monitoring of both complement inhibition and serum ECU levels is needed as intestinal disease can interfere with complement-blocking treatment. Increased doses of ECU may be necessary to maintain therapeutic blood levels of ECU and full complement blockade, especially if the intestinal disease is not under control.

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
AHAdam Hosszu
Adam Hosszu
ATAkos Toth
Akos Toth
DBDora Bianka Balogh
Dora Bianka Balogh
KCKata Cseko
Kata Cseko
JHJudit Hodrea
Judit Hodrea
AFAndrea Fekete
Andrea Fekete
Introduction and aims: Idiopathic pulmonary fibrosis is associated with a median survival of just 2-3 years after diagnosis. Current therapies ameliorate pulmonary functional decrement, but do not inhibit the progression of fibrosis or reduce mortality. Thus, effective anti-fibrotic therapies are desperately needed. Based on our previous results in other organs, we aimed to investigate whether Sigma-1 receptor (S1R) agonist fluvoxamine (FLU) can ameliorate pulmonary fibrosis. Methods: Fibrotic processes were induced with TGF-β or PDGF in A549 lung epithelial cells and primary fibroblasts isolated from the lungs of wt and S1R-/- mice. Cells were treated with FLU. Pulmonary fibrosis was induced in wild-type and S1R-/- mice by oropharyngeal bleomycin (BLM) administration. Mice were treated daily with FLU and sacrificed after 21 days. Results: FLU mitigated α-SMA production and F-actin formation in both A549 cells and primary lung fibroblasts after pro-fibrotic factor induction. The effect of FLU was not obeserved in fibroblasts isolated from S1R-/- mice. In mice, after 21 days pro-fibrotic factor Tgfb expression was unaltered, while Ctgf expression increased in the BLM group, but not in the wt BLM+FLU group. Elevated expressions of ECM components collagen I, collagen III and fibronectin were reduced to control levels in wt BLM+FLU mice. Evaluation of Masson's trichrome-stained sections underlined the massive anti-fibrotic effect of FLU. In vivo MicroCT showed more preserved aerated tissue area in wt BLM+FLU vs. wt BLM and S1R-/- BLM+FLU. Conclusions: Based on our preclinical data S1R may be a novel, effective drug target in the treatment of pulmonary fibrosis.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
AHAdam Hosszu
Adam Hosszu
DBDora Bianka Balogh
Dora Bianka Balogh
ATAkos Roland Toth
Akos Roland Toth
KCKata Cseko
Kata Cseko
JHJudit Hodrea
Judit Hodrea
AFAndrea Fekete
Andrea Fekete
Introduction and aims: Idiopathic pulmonary fibrosis is associated with a median survival of just 2-3 years after diagnosis. Current therapies ameliorate pulmonary functional decrement, but do not inhibit the progression of fibrosis or reduce mortality. Thus, effective anti-fibrotic therapies are desperately needed. Based on our previous results in other organs, we aimed to investigate whether Sigma-1 receptor (S1R) agonist fluvoxamine (FLU) can ameliorate pulmonary fibrosis. Methods: Pulmonary fibrosis was induced in wt and S1R-/- mice by oropharyngeal bleomycin (BLM) administration. Mice were treated daily with FLU and sacrificed after 21 days. Pulmonary functional parameters were measured by whole-body plethysmography. Results: After 21 days pro-fibrotic factor Tgfb expression was unaltered, while Ctgf expression increased in the BLM group, but not in the wt BLM+FLU group. Elevated expressions of ECM components collagen I, collagen III and fibronectin were reduced to control levels in wt BLM+FLU mice. Evaluation of Masson9s trichrome-stained sections underlined the massive anti-fibrotic effect of FLU. In vivo MicroCT showed more preserved aerated tissue area in wt BLM+FLU vs. wt BLM and S1R-/- BLM+FLU. Breathing rate increased in all groups at day 7 and normalized only in wt BLM+FLU mice by day 21. On day 7 tidal volume and minute volume were preserved in wt FLU-treated mice only, while decreased in wt BLM and S1R-/- BLM+FLU. Peak inspiratory flow and peak expiratory flow were more preserved in wt BLM+FLU mice on day 7 and returned to baseline by day 21 in all groups. Conclusions: Based on our preclinical data S1R may be a novel, effective drug target in the treatment of pulmonary fibrosis.